HeartBeam Names Ken Persen as Chief Technology Officer

Company Hires Cardiac Industry Veteran to Lead Technology Development SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, announced today the appointment of Ken Persen to the role of Chief Technology Officer. Persen has extensive technology, executive and start-up experience in … [Read more…]

Trinity Life Sciences Acquires Vancery’s Customer Research Technology

Asset Acquisition Enables Trinity to Better Connect with Healthcare Professionals WALTHAM, Mass.–(BUSINESS WIRE)–Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced it signed an asset purchase agreement for the acquisition of Vancery’s customer research technology. The investment expands Trinity’s insights and analytics product offerings, allowing the company to better connect with healthcare … [Read more…]

Gilead Sciences to Acquire MiroBio

– Acquisition Provides Gilead with MiroBio’s Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform – – MiroBio’s Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases Complements Gilead’s Inflammation Research and Development Strategy – FOSTER CITY, Calif. & OXFORD, England–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology … [Read more…]

ENDRA Life Sciences to Report Second Quarter 2022 Financial Results on August 15, 2022

ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NALFD—ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2022 on Monday, August 15, 2022 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast … [Read more…]

Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2022 financial and operating results on Thursday, August 11, 2022, following the close of the U.S. financial markets. Lineage management will also … [Read more…]

TecTraum Announces American Medical Association Issuing of First Ever Category III CPT Code for Treating Concussions

CPT code for emerging technology represents important milestone for therapeutic assessment and treatment of sports-related concussions. CLEVELAND–(BUSINESS WIRE)–TecTraum Inc., dedicated to providing the world’s first point-of-care treatment for concussions known as pro2cool®, announces today that the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code to help clinicians treat … [Read more…]

Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022, and invites investors to view the live … [Read more…]

The IBSA Class40 – the Craft That Will Take Alberto Bona to the Route Du Rhum – Was Launched in Trinité-Sur-Mer

The transatlantic regatta is the first stage of the three-year program Sailing into the Future. Together started by the Swiss pharmaceutical company, together with Alberto Bona. LA TRINITÉ-SUR-MER, France–(BUSINESS WIRE)–#IBSA–Latest-generation Class40, “scow” bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched … [Read more…]

Zoetis Announces Second Quarter 2022 Results 

Reports Revenue of $2.1 Billion, Growing 5%, and Net Income of $529 Million, or $1.12 per Diluted Share, Increasing 3% and 5%, Respectively, on a Reported Basis for Second Quarter 2022 Delivers 8% Operational Growth in Revenue and 9% Operational Growth in Adjusted Net Income for Second Quarter 2022 Reports Adjusted Net Income of $567 … [Read more…]

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

– LINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year – – GAAP net income of $37 million and adjusted EBITDA of $56 million; ended Q2 2022 with $504 million in cash and cash equivalents – – Completes Board of Directors authorized share repurchase program; repays remaining principal amount of the 2022 … [Read more…]